USSTOCK.TODAY
Market Closed
Log in Sign up

Allergan Aesthetics Announces Phase 4 Clinical Study Results for Adults Taking GLP-1

InvestorsHub +1 · ·by G4L

ABBV Abbvie Inc
$293.30 +0.68%
View chart & analysis →
  1. 1Allergan Aesthetics announced results from two Phase 4 clinical studies involving adults taking GLP-1 medications.
  2. 2Participants in the HARMONY IN DIVERSITY study recorded an average improvement of 42.4 points on the FACE-Q scale 30 days after treatment.
  3. 3In the HALO study, 95.7% of participants reported being satisfied or very satisfied with maintaining their appearance.

So what's the key point?

Allergan Aesthetics released study results regarding people taking weight loss medications. The study showed that 95.7% of participants were satisfied with how they looked.

Source InvestorsHub +1 · View original ↗

Related 3-line summaries

AbbVie signs $757 million licensing deal with Bryce Pharma for migraine treatment Pharmaceutical Technology · 5d agoAbbVie confirms efficacy of combination therapy in Phase 2 trial of Crohn's disease treatment ABBV-466 The Motley Fool +1 · Nov 2AbbVie reports third-quarter results beating estimates and announces dividend increase The Motley Fool +1 · Oct 31
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news